Fig. 7From: Therapeutic novelties in migraine: new drugs, new hope?Overview of patients (%) achieving > 50% reduction in migraine days in phase III clinical trials with erenumab. A darker bar indicates a higher dose. *ARISE; 70 mg vs. placebo, p = 0.010. STRIVE; 70 mg vs. placebo, p < 0.001; 140 mg vs. placebo, p < 0.001Back to article page